

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA: Icosapent ethyl with statin therapy for reducing the
risk of cardiovascular events in adults with elevated
triglycerides**

[ID3831]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Cardiovascular disease risk differs between ethnic groups.

The proportion of people from black and ethnic minority backgrounds is higher in people with insulin resistance (a risk factor for raised triglyceride levels) than the general population.

- | |
|---------------------------------------------------------------------------------------------------------------------|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---------------------------------------------------------------------------------------------------------------------|

Issues related to differences in prevalence or incidence of a disease cannot be addressed in a single technology appraisal.

- | |
|------------------------------------------------------------------------------------------|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|------------------------------------------------------------------------------------------|

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No. It is expected that the patient and carer organisations currently included on the stakeholder list will be able to provide the relevant insight into the equality issues highlighted.

Approved by Associate Director (name): Ross Dent

Date: 05/02/21